By FnF Correspondent | PUBLISHED: 02, Jan 2026, 13:04 pm IST | UPDATED: 04, Jan 2026, 10:48 am IST
In response to safety concerns regarding the risk of Nimesulide, the Union Health Ministry of India has banned the manufacturing, selling, and distributing of Nimesulide oral formulations that contain higher than 100 milligrams (mg) of Nimesulide per dose for human consumption as a precaution. This ban is now effective and was initiated as a means to safeguard public health.Nimesulide is a type of non-steroidal anti-inflammatory drug (NSAID) commonly used for pain relief and fever reduction. While it has been widely prescribed in India, experts and regulators have long worried about its potential to cause serious side effects, especially with higher doses.
According to the Health Ministry’s notification, high-dose oral forms (above 100 mg) are likely to pose risks to human health. The decision follows recommendations from the Drugs Technical Advisory Board (DTAB) and a key report by the Indian Council of Medical Research (ICMR), which highlighted safety concerns associated with the drug.
In fact, India’s health authorities had already banned nimesulide for children under 12 years of age many years ago because of similar safety concerns.
Although nimesulide has been a familiar product in India, its overall share in the painkiller market is relatively small. Analysts suggest the impact on major drugmakers may be limited, but smaller manufacturers that rely on sales of high-dose versions could be more affected.
For patients, doctors advise discussing alternative pain relief options with healthcare providers, especially if you regularly use or have been prescribed nimesulide.
by : Priti Prakash
The year 2025 dawned with New Delhi gazing lovingly into the mirror of its own expectations. After a...